A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma

Status

Ongoing, recruiting

Phase

Therapeutic confirmatory (Phase III)

Sponsor

Bristol Myers Squibb International Corporation

Enrolment target

578

Start

31 Aug 2023

Age 18 Years to any · Sex: All

• —

  Germany
• —

  Ireland
• —

  Hungary
• —

  Austria
• —

  Spain
• —

  Netherlands
• —

  Finland
• —

  Czechia
• —

  Denmark
• —

  Sweden
• —

  Belgium
• —

  Italy

+1 more sites — see the official record for the full list.